Published Healthcare & Pharmaceuticals Novel antibiotics We have developed lead BPL antagonist BPL199, which is active against Staphylococcus aureus BPL and Mycobacterium tuberculosis with > 44m-fold less selectivity for human BPL. By University of Adelaide
